1. Home
  2. FTFT vs BCAB Comparison

FTFT vs BCAB Comparison

Compare FTFT & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Future FinTech Group Inc.

FTFT

Future FinTech Group Inc.

HOLD

Current Price

$1.62

Market Cap

6.9M

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$1.70

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTFT
BCAB
Founded
N/A
2007
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Business Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
5.9M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
FTFT
BCAB
Price
$1.62
$1.70
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
170.6K
112.7K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.86
EPS
N/A
N/A
Revenue
$3,829,805.00
$300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
77.46
N/A
52 Week Low
$0.45
$0.12
52 Week High
$3.88
$6.52

Technical Indicators

Market Signals
Indicator
FTFT
BCAB
Relative Strength Index (RSI) 66.35 19.94
Support Level $0.98 $0.17
Resistance Level $1.70 $4.24
Average True Range (ATR) 0.16 0.36
MACD 0.13 -0.09
Stochastic Oscillator 65.66 7.67

Price Performance

Historical Comparison
FTFT
BCAB

About FTFT Future FinTech Group Inc.

Future FinTech Group Inc is engaged in the production and sale of fruit juice concentrates (including fruit purees and fruit juices), fruit beverages (including fruit juice beverages and fruit cider beverages) in the PRC. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The Company classified its business segments into Trading Commission and Consulting services, Fast-Moving Consumer Goods (FMCG), and Supply Chain Financing and Trading.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: